Prof. Dr. Dolores J. Schendel
Chief Executive Officer (CEO) and Chief Scientific Officer (CSO)
Since the 1970s, Prof. Dr. Dolores Schendel has been researching T cells and their abilities in immunotherapy and has accompanied the scientific and therapeutic turn of era in this field. Prof Schendel served as a University Professor for Immunology at the Ludwig-Maximilian-University, is the author of more than 200 scientific publications, has spent several decades as a scientific review board member in various research organizations such as the German Research Foundation, German Cancer Aid and the European Research Council among others. She is a recipient of the German Federal Order of Merit and the Bavarian Order of Merit and received the 'Deutsche Krebshilfe Preis', the award of the German Cancer Aid. From 1998 - 2013, Prof Schendel was Director of the Institute of Molecular Immunology of the German Research Center for Environmental Health at the Helmholtz Center in Munich. Following this, she founded the Trianta Immunotherapies GmbH (today "Medigene Immunotherapies GmbH). With the acquisition by Medigene in 2014, Dolores Schendel became Chief Scientific Officer and, in 2016, also the CEO of the company.
Prof Schendel completed her PhD in Genetics at the University of Wisconsin, USA, followed by post-doctoral training in immunology at University College London, UK. She developed her interest in tumor immunology while working at the Sloan-Kettering Institute for Cancer Research in New York.
Axel Sven Malkomes
Chief Financial Officer (CFO) and Chief Business Development Officer (CBO)
Axel Sven Malkomes has been appointed CFO and CBO of Medigene AG in April 2019 and has been active in the healthcare sector for more than 25 years. Most recently, he has been Managing Director of the Life Sciences Practice for the British bank Barclays in Europe. Previously, he served as Global Head of Healthcare & Chemicals Investment Banking at the French corporate and investment bank Société Générale. On the investor side, Mr. Malkomes has accumulated relevant experience during his several years with the UK private equity firm 3i as co-head of European Healthcare Investments. Previously, he had leading operational and corporate roles at the German pharmaceutical company Merck KGaA, i.e. as CEO of a Merck KGaA group company and as Head of Strategic Planning as well as Mergers & Acquisitions/Business Development, where he significantly participated in the initial set-up and build-out of the company's oncology business. During his international management career, the graduate in business administration gained extensive knowledge of the pharmaceutical industry and medical sciences through his professional activities and comprehensive further education.